Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 6/20 | 0.32 |
| ▸ | TDO2 | P48775 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22833740 | 0.73 | — | — | |
| SCHEMBL14769012 | 0.72 | CYP19A1 (0.43) | CYP19A1IDO1TDO2CYP3A4CYP11B1 | |
| SCHEMBL24934617 | 0.70 | RPS6KA2 (0.37) | CYP3A4CYP2D6 | |
| SCHEMBL22703075 | 0.69 | ACHE (0.33) | CYP19A1CHRM2CHRM4CHRM1 | |
| SCHEMBL12810523 | 0.69 | ACHE (0.33) | CYP19A1CHRM2CHRM4CHRM1 | |
| SCHEMBL24860311 | 0.69 | — | — | |
| SCHEMBL24934538 | 0.69 | — | — | |
| SCHEMBL20503156 | 0.68 | GAA (0.33) | — | |
| SCHEMBL1932876 | 0.67 | CYP19A1 (0.67) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL24934662 | 0.67 | CYP11B1 (0.34) | HSP90AA1HSP90AB1IDO1TDO2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151543-B | Fused tricyclic compounds and medical uses thereof | 日本烟草产业株式会社 | 2024-12-17 | — | — | CN | disclosed |
| US-20230025880-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230025880-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4116301-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2023-01-11 | — | — | EP | disclosed |
| CN-115151543-A | Fused tricyclic compounds and medical use thereof | 日本烟草产业株式会社 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025880-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | PC, PCK2, AGK | HSP90AA1 2793/4885HSP90AB1 2514/4885CYP19A1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.